Journals Publications Committee
The Journals Publications committee defines, manages, and oversees the publication activities of AASLD and to provide quality publications based on member needs.
Terms of Use and Privacy Policy
Use of the American Association for the Study of Liver Disease’s ("AASLD") World Wide Web pages (“AASLD website”) is subject to the terms and conditions (“Terms of Use”) set forth below.
Letter to the editor: The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 protein
Michel A. Struwe, Bernd Clement, Axel Scheidig – 12 May 2022
Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis
Kelly L. Hayward, Vikas Bansal, Patricia C. Valery, Katharine M. Irvine, Penny L. Wright, Caroline J. Tallis, Katherine A. Stuart, W. Neil Cottrell, Jennifer H. Martin, Elizabeth E. Powell – 12 May 2022
Impact of bacterial infections and spontaneous bacterial peritonitis prophylaxis on phage‐bacterial dynamics in cirrhosis
Jasmohan S. Bajaj, Marcela Peňa Rodriguez, Andrew Fagan, Sara McGeorge, Richard K. Sterling, Hannah Lee, Velimir Luketic, Michael Fuchs, Brian C. Davis, Masoumeh Sikaroodi, Patrick M. Gillevet – 12 May 2022
Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children
Nidhi P. Goyal, Sara B. Rosenthal, Chanod Nasamran, Cynthia A. Behling, Jorge E. Angeles, Mark H. Fishbein, Kathryn E. Harlow, Ajay K. Jain, Jean P. Molleston, Kimberly P. Newton, Patricia Ugalde‐Nicalo, Stavra A. Xanthankos, Katherine Yates, Nicholas J. Schork, Kathleen M. Fisch, Jeffrey B. Schwimmer, for the NASH Clinical Research Network – 12 May 2022
Mid‐upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic‐associated fatty liver disease: A population based observational study
Xiaoxiao Wang, Xiaohe Li, Rui Jin, Jia Yang, Rui Huang, Lai Wei, Feng Liu, Huiying Rao – 12 May 2022 – Metabolic‐associated fatty liver disease (MAFLD) is a series of liver diseases based on liver steatosis and metabolic disorders. Steatosis, as the core factor in MAFLD diagnosis, and fibrosis, as the major determinant of adverse outcomes of MAFLD, need to be assessed simply and accurately. In this study, we explored the significance of mid‐upper arm circumference (MUAC) in evaluating liver steatosis and fibrosis in patients with MAFLD.
Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh – 12 May 2022
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD
Ekaterina Smirnova, Mark D. Muthiah, Nicole Narayan, Mohamad S. Siddiqui, Puneet Puri, Velimir A. Luketic, Melissa J. Contos, Michael Idowu, Jen‐Chieh Chuang, Andrew N. Billin, Ryan S. Huss, Robert P. Myers, Sherry Boyett, Mulugeta Seneshaw, Hae‐Ki Min, Faridodin Mirshahi, Arun J. Sanyal – 12 May 2022
Erratum
12 May 2022